What's New
Ranitidine recall update (18/11/19)October 1, 2019
The availability of ranitidine is now extremely limited and famotidine is currently only funded for hospital use. PHARMAC is actively trying to source an alternative H2-antagonist (likely famotidine) to fund for community patients and have suggested it may be available on 1st Dec 2019. However, they will notify health professionals and update the online Schedule […]
Withdrawal of dosulepin (dothiepin) and doxepin from New ZealandJuly 18, 2019
Two tricyclic antidepressants (TCAs), dosulepin (dothiepin) and doxepin will no longer be available in New Zealand. When transitioning patients to alternatives, consider: Is a TCA still appropriate? TCAs are associated with a higher risk of adverse outcomes in people with cardiovascular disease and older adults. Individual psychiatric history. Switching therapy increases the risk of relapse […]